San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Driver Bioengineering is raising $23,603,313.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Wladimir Hogenhuis played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Driver Bioengineering
Chimeras mission is to reprogram life to end cancer, using therapies that restore dignity to patients. We do this with next generation, safer and more potent, CAR T therapeutics. Our mission is to improve the efficacy and safety of engineered cell therapies with the goal of transforming the promise of this new therapeutic class into a reality that offers the hope of cures for cancer patients with currently incurable tumor types. Cell therapies are comprised of harvesting immune cells from our body, engineering them to recognize specific tumor antigens, and then re-injecting them back into our bodies to seek and destroy tumor cells expressing the tumor antigen of interest. Cell therapies leverage the natural ability of immune cells to be activated, for example, only when they encounter specific target proteins, after which they can replicate and expand in numbers to overwhelm and eradicate tumors. Cell therapies can also persist in our bodies for long periods of time (weeks and months) and can continue to surveil for cancer cells long after treatment has been administered. As a result, cell therapies do not require patients to keep visiting their doctor to receive additional treatments.

To learn more about Driver Bioengineering, visit http://www.chimera.bio/

Contact:
Wladimir Hogenhuis, Chief Executive Officer
310-430-9893

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved